Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians

Table 3 HBV Seromarker prevalence by demographic and HIV status

	AIDS patients Pre-treatment time-point			Non-AIDS Baseline
Positive HBV Sero Markers	HBsAg	HBeAg ¹	HBV-infected ²	HBsAg N (%)	HBeAg ¹	HBV-infected 2 N (%)
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Sex:
Male	13 (17.6)	6 (46.2)	63 (86.3)	11 (14.3)	0 (0.0)	62 (87.3)
Female	16 (13.8)	4 (25.0)	95 (77.8)	30 (9.8)	8 (26.6)	227 (83.2)
P-value difference	0.48	0.23	0.14	0.26	0.17	0.39
Age:
10-24 years	1 (10.0)	1 (100.0)	10 (58.8)*	14 (16.9)	4 (28.6)	65 (83.3)
25-34 years	11 (19.3)	4 (36.4)	47 (92.2) *	17 (9.3)	2 (12.5)	135 (82.8)
35-44 years	13 (18.0)	4 (30.8)	59 (88.1) *	4 (6.4)	1 (25.0)	48 (82.7)
45-93 years	4 (7.8)	1 (25.0)	39 (84.8) *	6 (11.3)	1 (16.7)	42 (93.3)
P-value difference	0.31	0.54	< 0.0001	0.17	0.71	0.36
HIV status:
HIV-1	25 (17.6)	9 (36.0)	117 (78.5)	16 (10.1)	3 (18.8)	109 (76.8)*
HIV-2	3 (10.3)	0 (0.0)	24 (85.7)	24 (11.1)	4 (17.4)	174 (89.2)*
Dual Infection	1 (5.3)	1 (100.0)	17 (99.4)	1 (11.1)	1 (100.0)	7 (87.5)*
P-value difference	0.27	0.17	0.21	0.96	0.29	0.008
CD4:
< 200 cells μL-1³	14 (13.4)	5 (31.2)	87 (84.5)*
> 200 cells μL-1	11 (18.9)	3 (27.2)	51 (71.8)*
P-value difference	0.35	0.82	0.04
Total	29 (15.3)	10 (34.5)	158 (81.0)	41 (10.7)	8 (20.0)	290 (84.1)

¹ HBeAg status assessed in individuals who were HBsAg positive, ² Subjects who were HBsAg positive or HBcAb positive were considered to by HBV-infected. 164 (90%) of 183 HBsAg negative AIDS patients and 302 (89%) of 345 HBsAg negative non-AIDS individuals were tested for anti-HBc, 42 non-AIDS patients and 31 AIDS patients were HBsAg positive; 122 (74.5%) and 247 (98%) respectively had a positive anti-HBc result. ³ 189 AIDS patients had CD4 measurements, 109 had values <200 cell μL-1. * Chi-Square, Fisher's exact, Rank Sum or Kruskal-Wallis p-value <0.05; all but 14 of the non-AIDS patients had CD4 counts > 200 cells μL-1 25

ISSN: 1743-422X